Search research articles
Contact Us
Filters
Showing results (101-110 of 128) with videos related to
Page
of 13
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
February 11, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories
Emina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2014
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters
Solange Peters, Walter Weder, Urania Dafni, et al.
Pathologica
|
April 9, 2026
Standardizing the pathologic assessment of HER2-(ultra)low breast cancer: insights from a national Italian project
Bruna Cerbelli, Stefano Marletta, Michelina Amato, et al.
Critical Reviews in Oncology/Hematology
|
October 10, 2020
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
Umberto Malapelle, Giulio Rossi, Pasquale Pisapia, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
December 13, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry
Carol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
March 9, 2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies
Maria Rosaria Ricciardi, Maria Cristina Scerpa, Paola Bergamo, et al.
BMC Cancer
|
May 3, 2020
Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Cleo Keppens, Elisabeth M C Dequeker, Etienne Rouleau, et al.
Oncology Reports
|
April 22, 2008
Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases
Isabella Castellano, Anna Sapino, Riccardo Arisio, et al.
Virchows Archiv : an International Journal of Pathology
|
September 29, 2016
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
Zandra C Deans, Jose Luis Costa, Ian Cree, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
Erik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 128) with videos related to
Sort By:
Page
of 13
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
February 11, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories
Emina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2014
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters
Solange Peters, Walter Weder, Urania Dafni, et al.
Pathologica
|
April 9, 2026
Standardizing the pathologic assessment of HER2-(ultra)low breast cancer: insights from a national Italian project
Bruna Cerbelli, Stefano Marletta, Michelina Amato, et al.
Critical Reviews in Oncology/Hematology
|
October 10, 2020
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
Umberto Malapelle, Giulio Rossi, Pasquale Pisapia, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
December 13, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry
Carol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
March 9, 2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies
Maria Rosaria Ricciardi, Maria Cristina Scerpa, Paola Bergamo, et al.
BMC Cancer
|
May 3, 2020
Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Cleo Keppens, Elisabeth M C Dequeker, Etienne Rouleau, et al.
Oncology Reports
|
April 22, 2008
Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases
Isabella Castellano, Anna Sapino, Riccardo Arisio, et al.
Virchows Archiv : an International Journal of Pathology
|
September 29, 2016
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
Zandra C Deans, Jose Luis Costa, Ian Cree, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
Erik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Page
of 13